<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721032</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00011012</org_study_id>
    <nct_id>NCT00721032</nct_id>
  </id_info>
  <brief_title>Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia</brief_title>
  <official_title>Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventricular tachycardia (VT) is a morbid arrhythmia responsible for many sudden deaths and&#xD;
      ICD shocks. Despite much progress in the treatment of arrhythmia, VT remains a therapeutic&#xD;
      challenge. Most patients with VT have an implantable cardioverter defibrillator (ICD) for&#xD;
      secondary prevention of sudden cardiac death, however, an ICD merely treats VT, it does not&#xD;
      prevent VT. In patients with recurrent VT and ICD shocks, two strategies are available to&#xD;
      decrease the burden of VT. The first is antiarrhythmic drugs, and the second is VT ablation.&#xD;
      The aim of this study is to compare the efficacy of antiarrhythmic drugs and VT ablation&#xD;
      guided by MRI. VT can sometimes be suppressed with antiarrhythmic medications, however, these&#xD;
      are often ineffective, and carry a high burden of side effects. Many forms of VT can be cured&#xD;
      by selective destruction of critical electrical pathways with catheter ablation. A major&#xD;
      limitation in the ablation of VT, however, is the time required to localize scar tissue and&#xD;
      important pathways for targeting of lesions. Magnetic resonance imaging can now obtain&#xD;
      reliable images of scar location within the ventricles. Recent advances in electroanatomical&#xD;
      mapping systems allow operators to import pre-acquired images into the mapping system. The&#xD;
      aim of this study is to examine the feasibility of importing historic MRI scar maps of the&#xD;
      ventricles into the electroanatomical system and using such images to guide catheter&#xD;
      ablation, as compared to antiarrhythmic drug suppression of VT. We suspect that MRI guidance&#xD;
      will be especially useful in patients with &quot;unstable&quot; VT, i.e. VT that causes an abrupt drop&#xD;
      in blood pressure, and thus cannot be maintained in the electrophysiology (EP) lab for&#xD;
      mapping and entertainment purposes. Patients referred for VT ablation have ICDs. Through&#xD;
      previously completed animal work (Circulation 2004; 110(5): 475-82) and a human trial (2006&#xD;
      Sep 19;114(12):1277-84) we have demonstrated the safety of MRI in the setting of pacemakers&#xD;
      and implantable defibrillators using appropriate precautions. Through careful device&#xD;
      programming and using MRI sequences with limited energy exposure (specific absorption rate &lt;&#xD;
      2 W/kg) we will study the pre procedural myocardial anatomy of patients enrolled into this&#xD;
      study.&#xD;
&#xD;
      The primary endpoint will be lack of VT documented by implantable defibrillator (when&#xD;
      present) interrogation or Holter monitoring 6 months post ablation. The secondary endpoints&#xD;
      will be comparison of inducible arrhythmia at the end of the procedure, procedure time,&#xD;
      comparison of endocardial voltage mapping to scar on delayed enhancement MRI images, and&#xD;
      complications in each study arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left the institution&#xD;
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from ventricular tachycardia documented by implantable defibrillator cardioverter 6 months post ablation.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>inducible arrhythmia at the end of the procedure,</measure>
    <time_frame>During procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>During procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of endocardial voltage mapping to scar on delayed enhancement MRI images</measure>
    <time_frame>During procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of the procedure</measure>
    <time_frame>30 days following procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anti-arrhythmic group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI guided VT ablation</intervention_name>
    <description>Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Increased dose of amiodarone</intervention_name>
    <description>Increase the dose of amiodarone according to the following scheme:&#xD;
current dose -&gt; new dose 100 once daily (QD) -&gt; 200 QD; 200 QD -&gt; 400 QD; 300 QD -&gt; 600 QD; 400 QD -&gt; 600 QD</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Current treatment with amiodarone&#xD;
&#xD;
          -  Ischemic or non-ischemic cardiomyopathy&#xD;
&#xD;
          -  Monomorphic ventricular tachycardia at any cycle length, with &gt; 1 occurrence of the&#xD;
             same cycle length and morphology, at least one episode needs to be of sufficient&#xD;
             duration to result in a shock.&#xD;
&#xD;
          -  No contraindication to up titration of meds or to VT radiofrequency ablation (RFA)&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Primary antiarrhythmic medication other than amiodarone&#xD;
&#xD;
          -  Amiodarone at dose of 600 mg daily or higher&#xD;
&#xD;
          -  Polymorphic VT as culprit rhythm&#xD;
&#xD;
          -  History of metal exposure (welding)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Recent myocardial infarction&#xD;
&#xD;
          -  Planned coronary revascularization&#xD;
&#xD;
          -  Implantable cardiac devices not previously tested for safety in the setting of MRI&#xD;
&#xD;
          -  Glomerular Filtration Rate (GFR) &lt; 30 ml/min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2008</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventricular tachycardia (VT)</keyword>
  <keyword>Implantable cardioverter-defibrillator (ICD)</keyword>
  <keyword>Ablation</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Electrophysiology study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

